Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$0.53
+0.01 (+1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-7.3M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
53.3x
↑EV/EBITDA
N/A
•ROE
-519.9%
↓Gross Margin
N/A
•Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-11.7M · FCF $-12.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-11.7M | $-11.7M | $-9.1M | $-6.6M | $-5.0M | $-1.2M |
| EBITDA | $-11.4M | $-11.4M | $-7.8M | $-4.0M | $-4.5M | — |
| EPS | -7.16 | -7.16 | -82.60 | -88.25 | -126.00 | -24.00 |
| Balance Sheet | ||||||
| Debt/Equity | 0.10 | 0.10 | 1.65 | 0.27 | 0.10 | -0.05 |
| Current Ratio | 0.30 | 0.30 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-12.5M | $-12.5M | $-7.3M | $-5.6M | $-2.7M | — |
| Returns | ||||||
| ROE | -519.9% | -519.9% | -1289.5% | -162.6% | -65.1% | 65.3% |
| Valuation | ||||||
| P/E | 53.30 | 53.30 | — | — | — | — |
| P/B | 0.39 | 0.39 | 3.80 | 2.12 | 2.44 | — |
| Growth & Yield | ||||||
| EPS Growth | 91.3% | 91.3% | 6.4% | 30.0% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-87.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-82.60 → -7.16
Residual
-87.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.